Share on LinkedInShare on LinkedIn

ARTICLE · 19 JANUARY 2022

Milk Vitamin Patents Surprisingly Soured By Section 101

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

On Sept. 21, 2021, the U.S. District Court for the District of Delaware granted summary judgment that two formulation patents were directed to patent-ineligible subject matter.

United StatesIntellectual Property

On Sept. 21, 2021, the U.S. District Court for the District of Delaware granted summary judgment that two formulation patents were directed to patent-ineligible subject matter.1 The two ChromaDex patents concern compositions and pharmaceutical formulations of nicotinamide riboside, or NR, a vitamin present in cow's milk, for oral administration.

The ChromaDex Inc. v. Elysium Health Inc. decision was particularly surprising since the compositions and formulations at issue do not exist in nature and the U.S. Court of Appeals for the Federal Circuit and district courts have generally upheld patent claims to formulations of natural compounds under Title 35 of the U.S. Code, Section 101.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from